Using endophenotypes to examine molecules related to candidate genes as novel therapeutics: The "endophenotype-associated surrogate endpoint (EASE)" concept

Neuroscience Research

Volumn 99, Issue , 2015, Pages 1-7

  Yamasue, Hidenori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Autism spectrum disorder; Dopamine; Neuroimaging; Obsessive compulsive disorder; Oxytocin; Schizophrenia; Serotonin

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; OXYTOCIN; OXYTOCIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; BIOLOGICAL MARKER;

ARTICLE; BRAIN REGION; CORPUS STRIATUM; DISEASE MARKER; DISEASE SEVERITY; ENDOPHENOTYPE; ENDOPHENOTYPE ASSOCIATED SURROGATE ENDPOINT; GENE; GENOTYPE; HUMAN; LIMBIC CORTEX; LIMBIC SYSTEM; MOLECULE; MORPHOLOGY; OBSESSIVE COMPULSIVE DISORDER; PATHOGENESIS; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; SAMPLE SIZE; SOCIAL BEHAVIOR; WORKING MEMORY; ANIMAL; GENETIC PREDISPOSITION; GENETICS; MENTAL DISORDERS; METABOLISM;

ANIMALS; BIOMARKERS; ENDOPHENOTYPES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MENTAL DISORDERS;

EID: 84940586663     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2015.05.007     Document Type: Article

References (52)

1. Andari E., Duhamel J., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4389-4394.
2. Aoki Y., Abe O., Yahata N., Kuwabara H., Natsubori T., Iwashiro N., Takano Y., Inoue H., Kawakubo Y., Gonoi W., Sasaki H., Murakami M., Katsura M., Nippashi Y., Takao H., Kunimatsu A., Matsuzaki H., Tsuchiya K.J., Kato N., Kasai K., Yamasue H. Absence of age-related prefrontal NAA change in adults with autism spectrum disorders. Transl. Psychiatry 2012, 2:e178.
3. Aoki Y., Watanabe T., Abe O., Kuwabara H., Yahata N., Takano Y., Iwashiro N., Natsubori T., Takao H., Kawakubo Y., Kasai K., Yamasue H. Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial. Mol. Psychiatry 2015, 20:447-453.
4. Aoki Y., Yahata N., Watanabe T., Takano Y., Kawakubo Y., Kuwabara H., Iwashiro N., Natsubori T., Inoue H., Suga M., Takao H., Sasaki H., Gonoi W., Kunimatsu A., Kasai K., Yamasue H. Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. Brain 2014, 137:3073-3086.
5. Aoki Y., Yamasue H. Reply: Does imitation act as an oxytocin nebulizer in autism spectrum disorder?. Brain 2015, (Epub ahead of print).
6. Ashare R.L., Wileyto E.P., Ruparel K., Goelz P.M., Hopson R.D., Valdez J.N., Gur R.C., Loughead J., Lerman C. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study. Drug Alcohol Depend. 2013, 133:852-856.
7. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 2004, 161:1798-1805.
8. Bethlehem R.A., van Honk J., Auyeung B., Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology 2013, 38:962-974.
9. Cirulli E.T., Goldstein D.B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat. Rev. Genet. 2010, 11:415-425.
10. Domes G., Heinrichs M., Kumbier E., Grossmann A., Hauenstein K., Herpertz S.C. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol. Psychiatry 2013, 74:164-171.
11. Dunn B.K., Akpa E. Biomarkers as surrogate endpoints in cancer trials. Semin. Oncol. Nurs. 2012, 28:99-108.
12. Ellenberg S.S., Hamilton J.M. Surrogate endpoints in clinical trials: cancer. Stat. Med. 1989, 8:405-413.
13. Farrell S.M., Tunbridge E.M., Braeutigam S., Harrison P.J. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol. Psychiatry 2012, 71:538-544.
14. Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Stat. Med. 2012, 31:2973-2984.
15. Flint J., Timpson N., Munafò M. Assessing the utility of intermediate phenotypes for genetic mapping of psychiatric disease. Trends Neurosci. 2014, 37:733-741.
16. Furman D.J., Chen M.C., Gotlib I.H. Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology 2011, 36:891-897.
17. Giakoumaki S.G., Roussos P., Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 2008, 33:3058-3068.
18. Gordon I., Vander Wyk B.C., Bennett R.H., Cordeaux C., Lucas M.V., Eilbott J.A., Zagoory-Sharon O., Leckman J.F., Feldman R., Pelphrey K.A. Oxytocin enhances brain function in children with autism. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20953-20958.
19. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
20. Gottesman I.I., Shields J. Genetic theorizing and schizophrenia. Br. J. Psychiatry 1973, 122:15-30.
21. Grünblatt E., Hauser T.U., Walitza S. Imaging genetics in obsessive-compulsive disorder: linking genetic variations to alterations in neuroimaging. Prog. Neurobiol. 2014, 121:114-124.
22. Guastella A., Einfeld S., Gray K., Rinehart N., Tonge B., Lambert T., Hickie I. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2010, 67:692-694.
23. Hillis A., Seigel D. Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat. Med. 1989, 8:427-430.
24. Hoexter M.Q., de Souza Duran F.L., D'Alcante C.C., Dougherty D.D., Shavitt R.G., Lopes A.C., Diniz J.B., Deckersbach T., Batistuzzo M.C., Bressan R.A., Miguel E.C., Busatto G.F. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology 2012, 37:734-745.
25. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry 2007, 61:498-503.
26. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C., Aronowitz B., Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003, 28:193-198.
27. Inoue H., Yamasue H., Tochigi M., Abe O., Liu X., Kawamura Y., Takei K., Suga M., Yamada H., Rogers M.A., Aoki S., Sasaki T., Kasai K. Association between the oxytocin receptor gene and amygdalar volume in healthy adults. Biol. Psychiatry 2010, 68:1066-1072.
28. John B., Lewis K.R. Chromosome variability and geographic distribution in insects. Science 1966, 152:711-721.
29. LoParo D., Waldman I.D. The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis. Mol. Psychiatry 2015, 20:640-646.
30. Lázaro L., Bargalló N., Andrés S., Falcón C., Morer A., Junqué C., Castro-Fornieles J. Proton magnetic resonance spectroscopy in pediatric obsessive-compulsive disorder: longitudinal study before and after treatment. Psychiatry Res. 2012, 201:17-24.
31. Marsala S.Z., Gioulis M., Ceravolo R., Tinazzi M. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin. Neuropharmacol. 2012, 35:185-190.
32. Montag C., Sauer C., Reuter M., Kirsch P. An interaction between oxytocin and a genetic variation of the oxytocin receptor modulates amygdala activity toward direct gaze: evidence from a pharmacological imaging genetics study. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:S169-S175.
33. Nakao T., Okada K., Kanba S. Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings. Psychiatry Clin. Neurosci. 2014, 68:587-605.
34. Pauls D.L., Abramovitch A., Rauch S.L., Geller D.A. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat. Rev. Neurosci. 2014, 15:410-424.
35. Roussos P., Giakoumaki S.G., Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol. Psychiatry 2009, 66:997-1004.
36. Saito Y., Suga M., Tochigi M., Abe O., Yahata N., Kawakubo Y., Liu X., Kawamura Y., Sasaki T., Kasai K., Yamasue H. Neural correlate of autistic-like traits and a common allele in the oxytocin receptor gene. Soc. Cogn. Affect. Neurosci. 2014, 9:1443-1450.
37. Sauer C., Montag C., Reuter M., Kirsch P. Imaging oxytocin×dopamine interactions: an epistasis effect of CD38 and COMT gene variants influences the impact of oxytocin on amygdala activation to social stimuli. Front. Neurosci. 2013, 7:45.
38. Sauer C., Montag C., Wörner C., Kirsch P., Reuter M. Effects of a common variant in the CD38 gene on social processing in an oxytocin challenge study: possible links to autism. Neuropsychopharmacology 2012, 37:1474-1482.
39. Shahrestani S., Kemp A.H., Guastella A.J. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. Neuropsychopharmacology 2013, 38:1929-1936.
40. Shin D.J., Jung W.H., He Y., Wang J., Shim G., Byun M.S., Jang J.H., Kim S.N., Lee T.Y., Park H.Y., Kwon J.S. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol. Psychiatry 2014, 75:606-614.
41. Tost H., Kolachana B., Hakimi S., Lemaitre H., Verchinski B.A., Mattay V.S., Weinberger D.R., Meyer-Lindenberg A. A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13936-13941.
42. Tost H., Kolachana B., Verchinski B.A., Bilek E., Goldman A.L., Mattay V.S., Weinberger D.R., Meyer-Lindenberg A. Neurogenetic effects of OXTR rs2254298 in the extended limbic system of healthy caucasian adults. Biol. Psychiatry 2011, 70:E41-E42.
43. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: effects of 12 weeks of sertraline treatment on brain metabolites. Eur. Arch. Psychiatry Clin. Neurosci. 2015, 265:219-226.
44. Veening J.G., Olivier B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. Neurosci. Biobehav. Rev. 2013, 37:1445-1465.
45. Watanabe T., Abe O., Kuwabara H., Yahata N., Takano Y., Iwashiro N., Natsubori T., Aoki Y., Takao H., Kawakubo Y., Kamio Y., Kato N., Miyashita Y., Kasai K., Yamasue H. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry 2013, 71:166-175.
46. Watanabe T., Yahata N., Abe O., Kuwabara H., Inoue H., Takano Y., Iwashiro N., Natsubori T., Aoki Y., Takao H., Sasaki H., Gonoi W., Murakami M., Katsura M., Kunimatsu A., Kawakubo Y., Matsuzaki H., Tsuchiya K.J., Kato N., Kano Y., Miyashita Y., Kasai K., Yamasue H. Diminished medial prefrontal activity behind autistic social judgments of incongruent information. PLOS ONE 2012, 7:e39561.
47. Watanabe T., Yahata N., Kawakubo Y., Inoue H., Takano Y., Iwashiro N., Natsubori T., Takao H., Sasaki H., Gonoi W., Murakami M., Katsura M., Kunimatsu A., Abe O., Kasai K., Yamasue H. Network structure underlying resolution of conflicting non-verbal and verbal social information. Soc. Cogn. Affect. Neurosci. 2014, 9:767-775.
48. Wittes J., Lakatos E., Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat. Med. 1989, 8:415-425.
49. Yamasue H. Function and structure in social brain regions can link oxytocin-receptor genes with autistic social behavior. Brain Dev. 2013, 35:111-118.
50. Yamasue H., Suga M., Yahata N., Inoue H., Tochigi M., Abe O., Liu X., Kawamura Y., Rogers M.A., Takei K., Yamada H., Aoki S., Sasaki T., Kasai K. Reply to: Neurogenetic effects of OXTR rs2254298 in the extended limbic system of healthy caucasian adults. Biol. Psychiatry 2011, 70:e41-e42.
51. Yamasue H., Yee J.R., Hurlemann R., Rilling J.K., Chen F.S., Meyer-Lindenberg A., Tost H. Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J. Neurosci. 2012, 32:14109-14117.
52. van Ijzendoorn M.H., Bakermans-Kranenburg M.J. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology 2012, 37:438-443.